Learn how the use of novel linker platforms, including scaffolded architectures that incorporate multiple payloads, hydrophilic modifiers, and charged moieties, have expanded the potential of ADCs, overcoming earlier barriers of off-target toxicity, low solubility, high aggregation, and linker-payload instability leading to poor pharmacokinetic properties.
 |
Potency |
 |
Hydrophilicity |
||
|
Leverage your linker design to modify the drug-to-antibody (DAR) ratio so that you can modulate potency and hit your target therapeutic index. |
Linkers can modulate ADC hydrophilicity, improving solubility, minimizing aggregation, and reducing unwanted clearance.
|
||||
 |
Stability |
 |
Homogeneity |
||
| A linker needs to provide stability in blood plasma to protect from premature drug release and metabolic liabilities, yet remain labile at the target. | Ideal ADC linkers minimize heterogeneity, given that ADCs with mixed structure populations can include fractions with undesirable pharmacological properties and pose analytical challenges. |